Sangamo Therapeutics, Inc. reported impairment charges for the first quarter ended March 31, 2024. For the quarter, the company reported impairment of long-lived assets of $4,349,000 compared to $20,433,000 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5828 USD | +3.26% | -2.08% | +7.27% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.27% | 12Cr | |
+15.55% | 12TCr | |
+12.66% | 11TCr | |
-2.53% | 2.48TCr | |
+0.73% | 2.25TCr | |
-9.68% | 1.83TCr | |
-42.28% | 1.63TCr | |
-18.92% | 1.53TCr | |
+6.19% | 1.41TCr | |
+28.83% | 1.17TCr |
- Stock Market
- Equities
- SGMO Stock
- News Sangamo Therapeutics, Inc.
- Sangamo Therapeutics, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2024